| 2025-04-08 | -45.8% | earnings | MassDevice | CVRx stock drops on Q1 preliminary sales number miss - MassDevice |
| 2025-04-07 | -45.4% | earnings | Seeking Alpha | CVRx stock slides on preliminary revenue miss |
| 2025-04-07 | -45.4% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2023-02-21 | -42.8% | legal | SEC EDGAR | CVRX 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-05-09 | -42.1% | earnings | Seeking Alpha | CVRx downgraded at J.P. Morgan after Q1 sales miss |
| 2025-05-09 | -42.1% | analyst | Investing.com | JPMorgan cuts CVRx stock rating, slashes price target to $7 - Investing.com |
| 2024-10-29 | +36.9% | earnings | Seeking Alpha | CVRx GAAP EPS of -$0.57 misses by $0.10, revenue of $13.37M beats by $0.17M |
| 2024-10-29 | +36.9% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2025-05-08 | -36.8% | earnings | Seeking Alpha | CVRx GAAP EPS of -$0.53 beats by $0.04, revenue of $12.3M in-line |
| 2025-05-08 | -36.8% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2024-04-30 | -31.9% | legal | SEC EDGAR | CVRX 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-02-19 | +25.5% | news | PR Newswire | INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX - PR Newswire |
| 2026-02-19 | +25.5% | legal | marketscreener.com | CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - marketscreener.com |
| 2026-01-12 | -24.6% | earnings | Seeking Alpha | CVRx reports preliminary 2025 results, issues 2026 guidance |
| 2026-01-12 | -24.6% | legal | SEC EDGAR | CVRX 8-K: 1.01 and (SEC Filing) |
| 2026-01-12 | -24.6% | legal | SEC EDGAR | CVRX 8-K: 1.01, 2.02, 2.03, 8.01 (SEC Filing) |
| 2026-01-12 | -24.6% | earnings | Yahoo Finance | CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance - Yahoo Finance |
| 2026-01-12 | -24.6% | earnings | Investing.com | CVRx expects 11-18% revenue growth in 2026 following CPT code transition - Investing.com |
| 2024-10-30 | +24.4% | earnings | Seeking Alpha | CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript |
| 2023-12-26 | +22.4% | legal | SEC EDGAR | CVRX 8-K: 8.01 and (SEC Filing) |
| 2023-04-27 | +21.1% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2026-01-22 | +20.5% | news | Stock Titan | New heart implant trial could triple patients eligible for Barostim - Stock Titan |
| 2022-07-28 | +19.4% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2026-02-23 | +18.8% | news | Quiver Quantitative | $CVRX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative |
| 2026-02-23 | +18.8% | news | Quiver Quantitative | Insider Purchase: Director at $CVRX Buys 46,800 Shares - Quiver Quantitative |
| 2026-02-23 | +18.8% | news | Investing.com Nigeria | CVRx director Jain Mudit K. buys $297k in shares By Investing.com - Investing.com Nigeria |
| 2026-02-12 | -17.1% | earnings | MarketBeat | CVRx Q4 Earnings Call Highlights |
| 2026-02-12 | -17.1% | earnings | Associated Press Finance | CVRx: Q4 Earnings Snapshot |
| 2026-02-12 | -17.1% | analyst | GlobeNewswire | CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results |
| 2026-02-12 | -17.1% | earnings | Seeking Alpha | CVRx GAAP EPS of -$0.46 misses by $0.02, revenue of $16M beats by $0.17M |
| 2026-02-12 | -17.1% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2026-02-12 | -17.1% | earnings | Investing.com | Earnings call transcript: CVRx Q4 2025 sees stock surge despite earnings miss - Investing.com |
| 2026-02-12 | -17.1% | earnings | Yahoo Finance | CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2026-02-12 | -17.1% | earnings | TradingView | CVRX: Revenue and margin growth set the stage for accelerated expansion with new reimbursement and clinical trial catalysts - TradingView |
| 2024-07-29 | -17.1% | earnings | Seeking Alpha | CVRx, Inc. (CVRX) Q2 2024 Earnings Call Transcript |
| 2024-07-29 | -17.1% | earnings | Seeking Alpha | CVRx GAAP EPS of -$0.65 misses by $0.10, revenue of $11.8M beats by $0.02M |
| 2024-07-29 | -17.1% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2026-02-13 | -16.9% | earnings | Moby | CVRx, Inc. Q4 2025 Earnings Call Summary |
| 2026-02-13 | -16.9% | earnings | Seeking Alpha | CVRx outlines $63M-$67M 2026 revenue target as Barostim adoption accelerates with new CPT code |
| 2026-02-13 | -16.9% | earnings | Seeking Alpha | CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript |
| 2026-02-13 | -16.9% | analyst | Investing.com | Canaccord Genuity lowers CVRx stock price target to $10 on sector multiple decline - Investing.com |
| 2026-02-13 | -16.9% | legal | TradingView | CVRx, Inc. SEC 10-K Report - TradingView |
| 2025-07-16 | +16.7% | news | Seeking Alpha | CVRx shares rise on Medicare proposal for Barostim implant procedure |
| 2021-07-07 | -16.6% | legal | SEC EDGAR | CVRX 8-K: 5.03, 8.01 (SEC Filing) |
| 2026-01-13 | -16.5% | news | Quiver Quantitative | $CVRX stock is down 14% today. Here's what we see in our data. - Quiver Quantitative |
| 2026-01-13 | -16.5% | news | The Globe and Mail | CVRx Establishes At-The-Market Equity Offering Program - The Globe and Mail |
| 2026-01-13 | -16.5% | legal | GlobeNewswire | Wolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. Investors - GlobeNewswire |
| 2026-01-13 | -16.5% | news | The Globe and Mail | CVRx Issues 2026 Outlook and Expands Loan Facility - The Globe and Mail |
| 2022-04-25 | +14.9% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2024-11-04 | +14.1% | legal | SEC EDGAR | CVRX 8-K: 8.01 (SEC Filing) |
| 2026-01-15 | -14.1% | news | Seeking Alpha | CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2026-01-15 | -14.1% | news | Seeking Alpha | CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2025-01-13 | +13.7% | earnings | Seeking Alpha | CVRx says total Q4 revenue is expected to be between $15.2M and $15.3M |
| 2025-01-13 | +13.7% | legal | SEC EDGAR | CVRX 8-K: 2.02, 8.01 (SEC Filing) |
| 2026-02-11 | -13.4% | earnings | GuruFocus.com | What To Expect From CVRx Inc (CVRX) Q4 2025 Earnings |
| 2023-01-06 | -13.1% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for CVRx (CVRX) - Zacks Investment Research |
| 2021-07-03 | -12.7% | news | Zacks Investment Research | Should I buy CVRx (CVRX) - Zacks Investment Research |
| 2026-01-23 | +11.2% | news | Medical Device Network | CVRx’s stock up as heart failure device to be trialled in expanded patient group - Medical Device Network |
| 2026-02-24 | +11.1% | news | FinancialContent | INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX - FinancialContent |
| 2025-01-14 | +11.1% | analyst | Seeking Alpha | CVRx upgraded by William Blair to outperform |
| 2025-08-04 | -11.0% | earnings | Seeking Alpha | CVRx outlines $55M-$57M revenue target for 2025 as sales force transition nears completion |
| 2025-08-04 | -11.0% | earnings | Seeking Alpha | CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript |
| 2025-08-04 | -11.0% | earnings | Seeking Alpha | CVRx GAAP EPS of -$0.57 misses by $0.05, revenue of $13.6M beats by $0.38M |
| 2025-08-04 | -11.0% | legal | SEC EDGAR | CVRX 8-K: 2.02, 5.02 (SEC Filing) |
| 2021-07-01 | -10.4% | earnings | MarketBeat | CVRx (CVRX) Earnings Date and Reports 2026 - MarketBeat |
| 2025-02-05 | -10.2% | earnings | Seeking Alpha | CVRx targets $63M-$65M revenue in 2025 with strengthened sales strategy |
| 2025-02-05 | -10.2% | earnings | Seeking Alpha | CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript |
| 2026-04-09 | -9.1% | news | GlobeNewswire | CVRx, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire |
| 2026-04-09 | -9.1% | news | Stock Traders Daily | (CVRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily |
| 2025-12-01 | -8.4% | news | Investing.com | Johnson & Johnson sells CVRx (CVRX) shares worth $63,560 - Investing.com |
| 2025-12-01 | -8.4% | news | TipRanks | Johnson & Johnson Makes a Bold Move with CVRx Stock Sale! - TipRanks |
| 2025-12-01 | -8.4% | news | Investing.com UK | Johnson & Johnson sells CVRx (CVRX) shares worth $63,560 By Investing.com - Investing.com UK |
| 2021-07-11 | +8.1% | news | Barron's | GlaxoSmithKline Buys Up Shares of Medical-Device Maker CVRx - Barron's |
| 2024-09-03 | -8.0% | legal | SEC EDGAR | CVRX 8-K: 5.02 (SEC Filing) |
| 2021-07-08 | -7.7% | news | Stock Titan | Latest CVRX News - CVRx Reports Preliminary First Quarter 2026... - Stock Titan |
| 2025-07-02 | +7.7% | news | Seeking Alpha | CVRx: Sell-Off Ignores Its True Potential |
| 2025-07-02 | +7.7% | news | Seeking Alpha | Fear And Fundamentals: Why CVRx Stock’s Sell-Off Ignores Its True Potential (NASDAQ:CVRX) - Seeking Alpha |
| 2026-04-06 | -7.6% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | Is CVRx (CVRX) Stock Stable Now | Price at $9.19, Up 2.00% - Profit Potential - Cổng thông tin điện tử Tỉnh Sơn La |
| 2023-05-28 | -7.3% | news | CoinCodex | CVRx, Inc. (CVRX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2024-10-21 | +7.2% | analyst | Investing.com UK | Canaccord maintains Buy rating on CVRx stock By Investing.com - Investing.com UK |
| 2021-07-12 | +7.1% | legal | SEC EDGAR | CVRX 8-K: 5.02 (SEC Filing) |
| 2026-01-06 | +6.9% | news | Stock Titan | New billing codes may support wider use of Barostim heart failure therapy - Stock Titan |
| 2023-01-09 | -6.5% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2024-01-08 | -6.3% | legal | SEC EDGAR | CVRX 8-K: 2.02, 5.02, 8.01 (SEC Filing) |
| 2026-04-14 | -6.2% | news | The Globe and Mail | Lake Street Remains a Buy on CVRx (CVRX) - The Globe and Mail |
| 2026-04-14 | -6.2% | earnings | Investing.com Australia | William Blair reiterates CVRx stock rating on strong Q1 results By Investing.com - Investing.com Australia |
| 2023-07-25 | +6.0% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2025-05-02 | +6.0% | news | Intellectia AI | CVRX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2024-05-11 | +5.8% | earnings | MarketBeat | CVRx (CVRX) Stock Forecast and Price Target 2026 - MarketBeat |
| 2021-08-04 | -5.8% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | +5.7% | news | GlobeNewswire | CVRx Reports Preliminary First Quarter 2026 Financial Results |
| 2026-04-13 | +5.7% | earnings | Seeking Alpha | CVRx sees Q1 revenue in the range of $14.7M to $14.8M |
| 2026-04-13 | +5.7% | legal | SEC EDGAR | CVRX 8-K: 2.02, 8.01 (SEC Filing) |
| 2026-04-13 | +5.7% | news | Stock Titan | CVRx says Medicare approval rates improved as heart device sales rose - Stock Titan |
| 2026-04-13 | +5.7% | earnings | Stock Titan | CVRx (NASDAQ: CVRX) posts Q1 growth and advances BENEFIT-HF trial - Stock Titan |
| 2026-04-13 | +5.7% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Is CVRx (CVRX) Stock Near Support | Price at $7.49, Up 4.70% - Community Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-13 | +5.7% | earnings | TipRanks | CVRx Reports Strong Q1 Growth and Trial Progress - TipRanks |
| 2022-11-01 | +5.6% | legal | SEC EDGAR | CVRX 8-K: 1.01, 2.02, 2.03 (SEC Filing) |
| 2025-11-14 | +5.2% | news | Investing.com | Johnson & Johnson innovation sells $10,000 in CVRx shares - Investing.com |
| 2026-02-16 | -4.4% | earnings | GuruFocus.com | CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ... |
| 2026-02-15 | -4.4% | analyst | Simply Wall St. | Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results |
| 2026-02-15 | -4.4% | analyst | simplywall.st | Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results - simplywall.st |
| 2026-03-19 | +4.2% | legal | AD HOC NEWS | CVRx Inc Stock (ISIN: US12674F1003) Gains Momentum on Heart Failure Device Adoption Amid Medtech Sec - AD HOC NEWS |
| 2023-03-21 | -4.2% | legal | SEC EDGAR | CVRX 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-04-20 | +4.1% | news | GlobeNewswire | CVRx Announces Nomination of Michael Dale for Election to the Board of Directors |
| 2026-04-20 | +4.1% | news | Stock Titan | Former Abbott structural heart leader Michael Dale lands CVRx board nomination - Stock Titan |
| 2026-04-20 | +4.1% | news | Stock Traders Daily | Behavioral Patterns of CVRX and Institutional Flows - Stock Traders Daily |
| 2026-04-20 | +4.1% | news | Stock Titan | CVRx (CVRX) details 2026 virtual meeting, board nominees and pay - Stock Titan |
| 2021-11-04 | +4.0% | legal | SEC EDGAR | CVRX 8-K: 1.02, 2.02 (SEC Filing) |
| 2025-05-10 | -3.7% | earnings | Seeking Alpha | CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript |
| 2025-02-04 | -3.5% | earnings | Seeking Alpha | CVRx GAAP EPS of -$0.43 misses by $0.05, revenue of $15.3M beats by $0.08M |
| 2025-02-04 | -3.5% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | +3.5% | legal | SEC EDGAR | CVRX 8-K: 5.02 and (SEC Filing) |
| 2026-03-03 | +3.5% | earnings | Investing.com | CVRx approves performance stock units tied to 2026-2027 revenue goals - Investing.com |
| 2026-03-03 | +3.5% | news | Stock Titan | CVRx (NASDAQ: CVRX) officer receives major equity grants, sells shares to cover taxes - Stock Titan |
| 2022-12-20 | +3.3% | legal | SEC EDGAR | CVRX 8-K: 5.02 (SEC Filing) |
| 2024-01-31 | -3.2% | legal | SEC EDGAR | CVRX 8-K: 5.02 and (SEC Filing) |
| 2022-01-10 | -3.2% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2024-08-21 | -2.9% | news | ChartMill | CVRX Stock Chart | CVRX INC (NASDAQ:CVRX) - ChartMill |
| 2026-04-17 | -2.6% | news | Intellectia AI | CVRX Should I Buy - Intellectia AI |
| 2022-09-13 | -2.4% | analyst | TradingView | CVRX Forecast — Price Target — Prediction for 2027 - TradingView |
| 2024-01-25 | -1.8% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2025-11-25 | -1.7% | news | TipRanks | Johnson & Johnson Makes a Strategic Move with CVRx Stock Sale! - TipRanks |
| 2025-11-25 | -1.7% | news | Investing.com | Johnson & Johnson innovation sells $27,132 in CVRx shares - Investing.com |
| 2025-11-25 | -1.7% | news | Investing.com UK | Johnson & Johnson innovation sells $27,132 in CVRx shares By Investing.com - Investing.com UK |
| 2023-01-26 | +1.7% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2026-01-30 | +1.4% | news | GlobeNewswire | CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire |
| 2025-11-05 | +1.3% | earnings | Seeking Alpha | CVRx GAAP EPS of -$0.49 beats by $0.01, revenue of $14.7M beats by $0.54M |
| 2025-11-05 | +1.3% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2025-11-16 | +1.1% | news | Yahoo Finance | With 41% stake, CVRx, Inc. (NASDAQ:CVRX) seems to have captured institutional investors' interest - Yahoo Finance |
| 2024-03-30 | -1.1% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-04-09 | -1.1% | news | Seeking Alpha | CVRx, Inc.: Overreaction Creates Buying Opportunity |
| 2026-03-02 | +1.1% | news | GlobeNewswire | CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting |
| 2022-02-15 | -0.9% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2025-12-30 | -0.8% | news | simplywall.st | CVRx, Inc.'s (NASDAQ:CVRX) Popularity With Investors Under Threat As Stock Sinks 26% - simplywall.st |
| 2024-11-07 | -0.6% | news | Seeking Alpha | CVRx: Impressive Top-Line Growth Seems Priced In |
| 2025-11-10 | -0.5% | news | Investing.com | Johnson & Johnson innovation sells CVRx (CVRX) shares worth $536,309 - Investing.com |
| 2023-10-26 | +0.4% | legal | SEC EDGAR | CVRX 8-K: 2.02 and (SEC Filing) |
| 2023-06-16 | -0.4% | earnings | Seeking Alpha | CVRx Stock: Missing A Heartbeat (NASDAQ:CVRX) - Seeking Alpha |
| 2026-03-29 | -0.2% | news | Stock Traders Daily | How (CVRX) Movements Inform Risk Allocation Models - Stock Traders Daily |
| 2025-11-06 | +0.2% | news | Seeking Alpha | CVRx anticipates mid-teens growth in 2026 as sales force productivity and reimbursement improvements build momentum |
| 2025-11-06 | +0.2% | earnings | Seeking Alpha | CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript |
| 2026-04-26 | — | earnings | MarketBeat | CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat |
| 2021-06-30 | — | earnings | MarketBeat | CVRx (CVRX) Stock Price, News & Analysis - MarketBeat |
| 2021-06-30 | — | news | The Business Journals | Medical device firm CVRx goes public with $126M IPO - The Business Journals |